Skip to main content
. Author manuscript; available in PMC: 2019 Mar 6.
Published in final edited form as: Nature. 2018 Sep 5;561(7723):331–337. doi: 10.1038/s41586-018-0499-y

Figure 6 │. Anti-tumor activity of cytotoxic HS T-cells.

Figure 6 │

(A) Cartoon depicting experiment. (B) 51Cr-cytotoxicity assessing the cytolytic activity of HS T-cells at indicated E:T ratio against 5×103 targets; (B) HER2+ U87-GBM, (C) human- and murine-ECs, and (D) ALCAM-expressing leukocytes. THP-1, human monocytic cells. PMBC, peripheral blood mononuclear cells. Mean of triplicate ±SD; ***P=<0.001, one-way ANOVA with posthoc-Tukey’s. Three experiments from 3 donors done with similar results. (E) BLI of tumors (n=5–10 mice/group) after intravenous injection of T-cells indicated by arrow; quantified in (F). (G) Flow-cytometry quantifying TILs in explants. Error-bars are Mean±SD. Four experiments done with similar results, P<0.001. Tukey’s test. (H) Kaplan–Meier survival probability analyzed by Log-Rank test, ***P=0.00034. (I) Cartoon summarizing how the HS-platform transforms the obstructive cancer-endothelium into a selectively permissive inflammatory-like one, allowing for enhanced targeted-delivery of T-cells.